The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced obesity-associated breast cancer growth in a mouse model, according to a study being presented at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.
“Obesity is a significant risk factor for breast cancer, and while it is very preliminary data, our studies in mice suggest that these new anti-obesity drugs may be a way to reduce obesity-associated breast cancer…
Continue Reading
News Source: www.sciencedaily.com
Leave a Reply